ManaMed Introduces PlasmaFlow®, a Digital and Tubeless DVT Prevention Device (FDA 510(k) Cleared)
PlasmaFlow makes deep vein thrombosis (DVT) prevention simple for patients at home and in the hospital
SANTA ANA, Calif., Sept. 21, 2017 /PRNewswire/ -- ManaMed today announced that PlasmaFlow®, its FDA 510(k) cleared portable and tubeless DVT prevention device, is now available to medical practitioners and patients throughout the United States.
"We are thrilled that PlasmaFlow is now available to help reduce the risk of DVT, which affects as many as 900,000 Americans each year," said Trevor Theriot, Founder, President and CEO of ManaMed. "Blood clots are a silent killer, and we decided to step up the fight against DVT-related deaths."
PlasmaFlow is a portable, tubeless sequential compression device with multiple pressure settings. Designed for patient comfort, PlasmaFlow features step-up inflation technology, one-button operation, soft cuffs made of medical-grade material, up to 10 hours of rechargeable battery life, two LCD screens with a timer and pressure verification, and graduated, asymmetric compression.
Prescribed by a physician for home or clinical use, PlasmaFlow helps prevent the onset of DVT by stimulating blood flow in the extremities. PlasmaFlow is also indicated to enhance blood circulation, diminish post-operative pain and swelling, reduce wound healing time, aid in the treatment and healing of stasis dermatitis, venous stasis ulcers, arterial and diabetic leg ulcers, and chronic venous insufficiency, and reduce edema in the lower limbs. It can also be used as an aid in DVT prophylaxis for people expected to be stationary for long periods.
The risk of a blood clot is highest during surgery and in the weeks that follow. PlasmaFlow can be used throughout post-surgical recovery whenever the patient is sitting, resting, or lying down. It gives physicians a mechanical, drug-free option that supports a multimodal approach to venous thromboembolism (VTE) prevention for higher-risk orthopedic surgery patients, without the bleeding risk or blood monitoring associated with some anticoagulant medications.
"With FDA 510(k) clearance, PlasmaFlow is a major step forward in DVT prevention," added Theriot. "We will remain on the cutting edge, developing innovative therapy devices that make daily life better for patients."
Editor's note (2026): This release describes the original PlasmaFlow (FDA 510(k) cleared, K160318), which remains available. ManaMed's newer model, PlasmaFlow X, is also FDA 510(k) cleared (K251446). ManaMed, Inc. is now ManaMed LLC, headquartered in Denton, Texas.
ABOUT MANAMED
ManaMed designs, develops, and distributes orthopedic solutions that keep active, high-performing people in the game and back-on-track following injury or surgery. Our extensive catalog spans vascular and electrotherapies, assisted mobility, electrical stimulation, and DVT prevention products. We partner with orthopedists, physical therapists, surgeons, and DME companies across the US to keep patients of all ages and backgrounds healthy and comfortable while on the path to recovery. We welcome opportunities to work together to solve tough challenges with innovative solutions. For more information, visit manamed.com, or talk to one of us by emailing support@manamed.com or calling 1.888.508.0712.
Media Contact:
ManaMed LLC
Marketing@ManaMed.com
888.508.0712
2612 Sirius Dr.
Denton, TX 76208
###
ManaMed is dedicated to providing innovative recovery solutions that empower clinicians and patients alike. ManaMed is a global leader that designs, develops, and distributes orthopedic solutions that keep active, high-performing people in the game and back on track following injury or surgery.
Media contact